Abstract. Progress in diagnosis, treatment, and epidemiology of human African trypanosomiasis (sleeping sickness) depends on the existence of specific and sensitive diagnostic tools. Inherent shortcomings of serologic and parasitologic diagnostic methods can be overcome by molecular techniques. Therefore, we have developed a new polymerase chain reaction (PCR) test using primers derived from the recently identified sequence of the Trypanosoma brucei gambiensespecific glycoprotein (TgsGP). The specificity of the TgsGP-PCR was evaluated on DNA extracted from 73 different trypanosome populations belonging to diverse taxonomic groups that were isolated from various host species, and from different geographic origins. The TgsG-PCR was shown to be specific for T. b. gambiense and was suitable for detection of trypanosome DNA in blood samples of patients with confirmed sleeping sickness.
INTRODUCTION
Trypanosoma brucei gambiense and T. b. rhodesiense are extracellular protozoan parasites causing human African trypanosomiasis (HAT or sleeping sickness). Trypanosoma b. brucei is not infectious to human but causes nagana in domestic ruminants. All three subspecies are morphologically indistinguishable and can be harbored by domestic animals as well as wildlife. [1] [2] [3] [4] Trypanosoma b. brucei is sensitive to lysis by normal human serum (NHS) while T. b. gambiense and T. b. rhodesiense are resistant, although the latter subspecies can revert to a human serum-sensitive phenotype. 5, 6 The parasites are transmitted by tsetse flies (Glossina spp.) in sub-Saharan Africa. Therefore, T. b. gambiense is present in western and central Africa, while T. b. rhodesiense is restricted to eastern Africa. 7 Epidemics of T. b. gambiense are currently threatening approximately 50 million people, mainly in the Democratic Republic of the Congo, Angola, southern Sudan, and northern Uganda, with an estimated number of 300,000-500,000 infected patients. 8 Control of T. b. gambiense sleeping sickness relies heavily on active case detection and correct treatment. Screening of the population at risk is done by antibody detection with the card agglutination test for trypanosomiasis (CATT) and subsequent parasitologic detection performed on the seropositive individuals. 9, 10 Although proven to be very useful, the CATT has its limitations. A variable percentage of the screened population that is seropositive in the CATT shows no clinical sign of infection and/or cannot be confirmed by parasite detection. As shown by Simarro and others 11 and Garcia and others, 12 the parasitologic detection techniques have limited sensitivity; thus, it is possible that at least some of these unconfirmed CATT-seropositive individuals are indeed infected. Furthermore, cured patients can remain CATT seropositive for up to three years due to persisting circulating antibodies, thus prohibiting the use of antibody tests for assessment of treatment success. 13 For reasons of erroneous stage determination or treatment refractoriness, patients sometimes relapse after treatment. Studies on improved stage determination, therapy, drug resistance, and new drugs are being undertaken but are hampered by the low sensitivity of the parasitologic diagnostic methods. [14] [15] [16] [17] In principle, DNA detection techniques such as the polymerase chain reaction (PCR) might partially overcome at least some of these diagnostic problems due to their alleged increased sensitivity and specificity. Indeed, PCR tests for detection of T. brucei DNA have been developed and used in several studies on sleeping sickness. [18] [19] [20] [21] [22] [23] The primers used in these studies were derived from the repetitive nuclear DNA or the expression site-associated genes (ESAGs) ESAG 6 and 7. [24] [25] [26] [27] Although, their specificity is restricted to the subgenus Trypanozoon, they are unable to distinguish between T. brucei subspecies.
However, for epidemiologic studies, discrimination of the three T. brucei subspecies within the host or the vector is essential. 4 Within this context, various molecular techniques have been applied, such as isoenzyme analysis, restriction fragment length polymorphism (RFLP), random amplified polymorphic DNA analysis (RAPD), karyotype analysis, polymorphism analysis within the sequences of the variant surface glycoprotein (VSG), mini-satellites and microsatellites, kinetoplast DNA, and an internal transcribed spacer 1 of rDNA. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] These techniques often require prior expansion of trypanosome populations in laboratory animals or in culture medium and involve multiple and timeconsuming analytical steps. Taking into account the low isolation success rates observed for T. b. gambiense, and the fact that during primary isolation, and subsequent expansion, initially mixed-infection populations can be lost due to selection for the best growing one, the need for simplified techniques able to discriminate between the three T. brucei subspecies within the animal reservoir and the vector is obvious. 4 The purpose of this study was to develop a simple PCR test capable of specific detection of the DNA of T. b. gambiense. The recently published sequence of the T. b. gambiensespecific glycoprotein (TgsGP) served as the base for the primer design. 43 When tested on 73 different trypanosome populations belonging to various taxonomic groups and originating from different hosts and geographic locations, the TgsGP-PCR was shown to be specific for T. b. gambiense. Furthermore, the TgsGP-PCR was also successfully applied in the detection of T. b. gambiense DNA in total DNA extracts from blood samples of patients with confirmed sleeping sickness. All trypanosomes were kept as cryostabilates in liquid nitrogen. The bloodstream form trypanosomes were first expanded in OF1 mice (IFFA CREDO, Charles River Laboratories, Brussels, Belgium) and subsequently in Wistar rats (Harlan, Horst, The Netherlands). The parasites were purified from a blood using a DAE52 column (Whatman, Maidstone, Kent, UK) according to the procedure of Lanham and Godfrey. 52 The eluted parasites were centrifuged at 1,200 × g for 30 min at 2°C. The sediment was washed three times with phosphate saline glucose buffer (PSG buffer, 38 mM Na 2 HPO 4 , 2 mM NaH 2 PO4, 29 mM NaCl, 83 mM glucose, pH 8) by resuspension and centrifugation. The procyclic forms (four isolates of T. b. gambiense: Bage, Nabe, Pakwa, and Seka, one of T. b. rhodesiense: O4O4, one of T. b. brucei: Ketri, and one of T. theileri: Melsele; Table 1 ) were grown in a kit for in vitro isolation or in Cunningham culture medium. 53 They were separated from the culture media by centrifugation at 1,200 × g for 30 min at 2°C. The sediment was washed three times with phosphate glucose sacharose buffer (38 mM Na 2 HPO 4 , 2 mM NaHPO 4 , 29 mM NaCl, 83 mM glucose, 100 mM sacharose, pH 8) by resuspension and centrifugation. All trypanosome sediments were stored at -70 C°.
Plasmodium falciparum parasites were obtained from the Institute for Tropical Medicine (Antwerp, Belgium). They were grown in BALB/c mice (Harlan). Infected red blood cells were obtained from blood collected by heart puncture into tubes containing heparin at a parasitemia of 30%.
Extraction of DNA from human blood, purified trypanosomes, and P. falciparum. A total of 92 human blood samples from individuals in Côte d'Ivoire were analyzed by a PCR. They were collected during a medical survey that was carried out in April-May 2000, where, for regular diagnostic purposes, 2 mL of venous blood was collected into tubes containing heparin. Among them were 41 samples that were found positive in the CATT, from which 14 samples were confirmed positive by a miniature anion exchange centrifugation technique (mAECT). The other 51 samples were collected during the same survey from the CATT/mAECTnegative persons. After serologic and parasitologic tests were performed, 180 L of the remaining blood was mixed with 180 L of AS1 storage buffer (Qiagen, Westburg, Leusden, The Netherlands). All blood samples were stored for one month in the dark at -20°C. In addition, 10 control blood samples were collected from healthy Belgian volunteers. Total DNA was extracted using the Qiamp blood DNA extraction protocol (Qiagen). The DNA was collected into 200 L of AE elution buffer (Qiagen) and precipitated using 20 L of 3 M sodium acetate (pH 5.2) and 400 L of pre-chilled 100% ethanol. Samples were then centrifuged (for five minutes at 8,000 × g), and the pellet was rinsed once with pre-chilled 70% ethanol and centrifuged for three minutes at 8,000 × g. The concentrated DNA was resuspended in 20 L of water. The typical DNA yield corresponded to 10 g/ml as determined by spectrophotometric analysis.
To determine the analytical PCR detection limit, purified trypanosomes in PSG buffer were first counted in a counting chamber under a light microscope. A human blood sample from a volunteer was spiked with 100,000 purified trypanosomes/ml of blood. From this spiked blood, 10-fold serial dilutions to one trypanosome/ml were prepared. These dilutions were processed immediately with proteinase K solution (20 mg/ml) and AL lysis buffer according to the protocol of Qiagen. The DNA was extracted using a blood DNA extraction kit (Qiagen) and precipitated as described earlier.
The extraction of DNA purified trypanosomes was performed as follows: 20 L of purified trypanosome sediment (2 × 10 7 cells) was resuspended in 200 L of PSG buffer, and the trypanosome DNA was extracted using a blood DNA mini kit (Qiagen). The DNA was eluted in 200 L of the AE buffer (Qiagen). Its typical yield was 30 g/ml as determined by spectrophotometric analysis.
For extraction of P. falciparum DNA, 180 L of infected mouse blood was treated with 20 L of proteinase K solution (20 mg/ml) and 200 L of AL lysing buffer (Qiagen). The DNA was extracted using the blood DNA extraction kit, and was eluted in 200 L of AE buffer at a concentration of 20 g/ml.
TgsGP-PCR. The primers were derived from the sequence of the T. b. gambiense-specific glycoprotein (TgsGP; accession number AJ277951). 43 They were designed using the GenBank homology search program to target the region lacking significant similarity with already known DNA sequences. The following sequences were selected: sense primer: 5-Ј GCTGCTGTGTTCGGAGAGC-3Ј and anti-sense primer: 5Ј-GCCATCGTGCTTGCCGCTC-3Ј. The presence of amplifiable DNA in the extracted human samples was checked by PCR with human ␤-actin-specific primers. The ␤-actin PCR was performed according to the protocol described by Kinoshita and others. 54 All PCR amplifications were performed using 10-100 ng of the DNA extracted from purified parasites, or 10 L of the DNA extracted from human blood samples. The DNA template was amplified in 50 L of PCR mixture containing 1× PCR buffer (20 mM Tris-HCl pH 8.7, 100 mM KCl, 50 mM (NH 4 ) 2 SO 4, Q solution), 1.5 mM MgCl 2 , 200 M each of the four dNTPs, 0.5 M of each primer, and 2.5 units of HotStar Taq DNA polymerase (Qiagen). All PCRs were performed using a T3 Thermocycler (Biometra, Westburg, Leusden, The Netherlands). The TgsGP-PCR conditions were as follows: sample incubation for 15 minutes at 95°C followed by 45 cycles of one minute at 94°C, one minute at 63°C, and one minute at 72°C, and a final extension for 10 minutes at 72°C. A 20-L sample of each PCR product was analyzed by electrophoresis in a 2% agarose gel. The gels were stained with ethidium bromide (1 g/ml) (Sigma, St. Louis, MO) and analyzed on an Imagemaster Video Detection System (Pharmacia, Bucks, United Kingdom). To increase the analytical PCR detection limit, a second TgsGP-PCR was performed with one microliter of the first PCR product. As negative PCR controls, human DNA sample extracted from blood samples of healthy volunteers and a PCR mixture without the DNA template were run along with the other samples. Samples were collected as a part of routine diagnosis of patients, as prescribed by the World Health Organization (WHO). The study was approved by the ministry of health from Côte d'Ivoire and oral consent was systematically collected from all patients.
RESULTS

Specificity and detection limit of the TgsGP-PCR.
Using primers that recognize the T. gambiense TgsGP gene, we developed a PCR protocol in which a 308-base pair (bp) PCR product was expected for specific amplification. Results obtained with this PCR are shown in Table 1 (Table 1 ). Unexpectedly, the T. b. gambiense Abba and Ligo strains were TgsGP-PCR negative. When subjected to the SIIT, all 13 TgsGP-positive populations were found to be fully resistant to NHS, while the Abba and Ligo strains were initially found to be sensitive, although they reverted to a resistant phenotype in mice after repeated injection with NHS.
The detection limit of the TgsGP-PCR was evaluated on the series of human blood samples spiked with purified trypanosomes. After a single PCR, the detection limit reached 1,000 trypanosomes/ml of blood. This detection limit increased to 10 trypanosomes/ml of blood when the TgsGP-PCR was repeated using an aliquot of the first PCR product.
Detection of T. b. gambiense DNA in total extracts from blood samples of patients with confirmed sleeping sickness by the TgsGP-PCR. Figure 1 shows representative results of the TgsGP-PCR obtained with total DNA extracts from human blood samples. As expected, only one PCR product of 308 bp was amplified in the DNA extracts of parasitologically confirmed patients with sleeping sickness, and in a T. b. gambiense-positive control (Figure 1, lanes 1-4 and 9) while DNA extracts from the CATT/mAECT-negative African individuals and healthy Belgian volunteers remained TgsGP-PCR negative (Figure 1, lanes 5-8) . Since malaria is very common in regions where sleeping sickness is present, the TgsGP-PCR should not amplify Plasmodium DNA. No amplification product was obtained with DNA extracted from P. falciparum (Figure 1, lane 10) .
The diagnostic potential of the TgsGP-PCR was evaluated on a collection of human blood samples from Côte d'Ivoire and Belgium. All samples were subjected to an initial PCR, followed by a second PCR on an aliquot of the first reaction product. The results are shown in Table 2 
DISCUSSION
The purpose of this study was to develop a new PCR test for specific detection of T. b. gambiense DNA. The PCR primers used were derived from the sequence of the recently identified TgsGP gene, which encodes a T. b. gambiensespecific flagellar pocket glycoprotein. 43 Since this gene shares certain similarities with the 5Ј-terminal half of the T. b. brucei IlTat 1.23 VSG gene, the primer sequences were selected from regions of low similarity. To avoid primer-dimer formation, both 3Ј ends did not contain any complementary base pairs and were devoid of any long stretches of guanidine and cytosine repeats. A hot start step was included to avoid generation of non-specific PCR products. The TgsGP-PCR specificity was evaluated with 73 different trypanosome populations. An expected 308-bp specific PCR product was generated solely when DNA from T. b. gambiense was tested. Interestingly, two alleged T. b. gambiense strains, i.e., Abba and Ligo, that were isolated from patients with sleeping sickness in Côte d'Ivoire remained negative in the TgsGP-PCR. These strains were previously identified as being distinct from the conventional T. b. gambiense group 1, sharing molecular characteristics with Nigerian strains of T. b. brucei. 4, 35, 38, 55 This initial characterization was based on cluster analysis of the RFLP pattern derived from the ribosomal non-transcribed spacer region. 35 Since the TgsGP-PCR targets a gene that is associated with NHS resistance, we subjected the Abba and Ligo strains to the SIIT. 43, 51 Initially, both strains were sensitive to lysis by NHS. When grown in mice under NHS pressure, they converted to an NHS-resistant phenotype, confirming earlier reports that some alleged T. b. gambiense strains from humans in Côte d'Ivoire can exert different inducible levels of NHS resistance. 5, 6, 56, 57 Together, these results indicate that the TgsGP-PCR specifically identifies conventional T. b. gambiense strains that are persistently resistant to NHS.
Previous reports have described other molecular techniques for the specific detection of T. b. gambiense. MathieuDaudé and others 40 and Schares and others 41 reported on methods involving a first PCR step or nested PCR, followed by hybridization with a T. b. gambiense-specific probe that was derived from the sequence of the kinetoplast minicircle DNA variable regions. A risk associated with targeting kinetoplast minicircle DNA for diagnostic purposes is connected with the high rate of genetic evolution within this sequences, as it is for VSG genes. Indeed, other groups have developed PCR tests based on T. b. gambiense VSG sequences (AnTat 11.17 and LiTat 1.3), but observed that some T. b. gambiense strains from northwestern Uganda and Cameroon remained negative in these PCRs due to the absence of the corresponding VSG genes within their genome. 40, [58] [59] [60] Although the TgsGP gene is located on a telomere, it does not belong to a VSG expression site (ES), and as such is not subjected to ES-associated antigenic variation. 43, 60 Therefore, the TgsGP-PCR may prove to be a more reliable tool in the detection of T. b. gambiense, e.g., for studying its animal reservoir and its transmission dynamics.
Although the geographic distribution of T. b. gambiense and T. b. rhodesiense is classically confined to west and central Africa, and eastern Africa, respectively, recent reports indicate the presence of T. b. rhodesiense outside the traditional foci in southeastern Uganda. 7, 61 Isolates from the Masindi district in midwestern Uganda were shown to be T. b. gambiense as well as T. b. rhodesiense. 61 Since both trypanosomes show differential drug sensitivity, a correct diagnosis between T. b. gambiense and T. b. rhodesiense is essential for successful drug treatment and may be facilitated by a simple molecular technique, such as the TgsGP-PCR.
One advantage of the TgsGP-PCR is its simplicity compared with other techniques used for differentiation of the three T. brucei subspecies, such as isoenzyme analysis, karyotype analysis, RFLP, RAPD, which usually require high numbers of parasites or involve a comparative analysis of genomic patterns. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] By running two subsequent TgsGP-PCRs on the same sample of spiked blood, a detection limit of 10 trypanosomes/ml of blood could be obtained. This is comparable with that reported with a two-run ESAG6/7 PCR or a repetitive nuclear DNA-based PCR used with blood samples from patients with sleeping sickness. 18, 21 Whether the detection limit of the TgsGP-PCR will be low enough to identify all patients with sleeping sickness caused by T. b. gambiense in a specific population remains to be investigated. Indeed, in the present study, only the CATTpositive cases that were confirmed by the mAECT (34% of the samples) were positive in the TgsGP-PCR after two amplification reactions, while all the parasitologically unconfirmed CATT-positive samples remained negative. Similar results were obtained by Kyambadde and others, who found that 60% of the CATT-positive samples were negative when tested by both the hematocrit centrifugation technique and the repetitive nuclear DNA-based PCR, while all the parasitologically confirmed CATT-positive samples were also positive in their PCR. 23 Since there is evidence that some of the unconfirmed CATT-positive individuals are indeed infected, lowering the detection limit of the PCR methods, e.g., by analyzing a larger volume of blood, may be necessary. 12 
